Your session is about to expire
← Back to Search
Pembrolizumab/Vibostolimab for Blood Cancers
Study Summary
This trial will test a new cancer treatment, made of two drugs, to see if it is safe and works well against hematological malignancies.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have fully recovered from any major surgery before starting the study.I have a known history of HIV.I had radiotherapy less than 2 weeks before starting the study.I have not received a live vaccine in the last 30 days.I have had serious heart problems in the last year.I need urgent treatment to reduce my PMBCL tumor size.I have an autoimmune disease treated with medication in the last 2 years.My cancer did not respond or came back after CAR-T-cell therapy, or I can't receive this therapy.I am not pregnant or breastfeeding and either can't have children or use effective birth control.My condition is a specific type of blood cancer.I have a history of specific blood disorders related to my multiple myeloma.I can provide a recent bone marrow sample for testing.I have DLBCL or NHL and cannot undergo standard treatments anymore.I am currently being treated for an infection.I have had a stem cell or organ transplant in the last 5 years.My cancer did not respond to or I can't have CAR-T-cell therapy.I have Mantle cell lymphoma and have been treated with a Bruton's tyrosine kinase inhibitor.I have a specific type of blood cancer that is not common DLBCL or NHL.My organs are functioning well.I have both active hepatitis B and C infections.My cancer is a type of lymphoma or multiple myeloma that has returned or did not respond to treatment.My cancer is a type of lymphoma or multiple myeloma that has returned or did not respond to treatment.I am HBsAg positive but have been on HBV therapy for 4 weeks with an undetectable viral load.I need treatment for fluid buildup in my chest or abdomen recently.I have DLBCL or NHL and cannot undergo standard treatments anymore.I have had another type of cancer in the past.I have Mantle cell lymphoma and have been treated with a specific type of cancer therapy before.My multiple myeloma has affected my brain or spinal cord.My EBV-positive lymphoma is linked to an organ transplant.
- Group 1: Pembrolizumab/vibostolimab coformulation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can you tell me how many different locations this trial is taking place?
"There are a total of 13 locations currently recruiting patients for this clinical trial, these include University of Chicago Medical Center (Site 0005) in Chicago, Jewish General Hospital (Site 0032) in Montreal and University of Texas MD Anderson Cancer Center ( Site 0014) in Houston."
What are the goals of this particular clinical trial?
"The purpose of this trial, which will last for up to 6 weeks, is to document the number of adverse events experienced by participants. Additionally, researchers will be looking at disease control rate (DCR) and duration of response (DOR) as secondary outcomes. Finally, they hope to gain insights into the maximum concentration (Cmax) of Vibostolimab in plasma."
What are the dangers that come with taking Pembrolizumab/vibostolimab coformulation?
"Pembrolizumab/vibostolimab coformulation is classified as a Phase 2 drug, so there is some data supporting its safety. However, because this trial lacks evidence of efficacy, it received a score of 2."
How many people have been chosen to participate in this clinical trial?
"One hundred and eighty individuals that meet the pre-specified inclusion criteria are required for this study. These potential participants can be recruited from different hospitals, such as University of Chicago Medical Center in Illinois or Jewish General Hospital in Montreal, Quebec."
Are there any patients currently being recruited for this study?
"Yes, as of today this clinical trial is still looking for participants. According to the information on clinicaltrials.gov, the study was first posted on September 28th, 2021 and has since been updated on November 17th, 2022."
Are there other examples in the medical literature of Pembrolizumab and vibostolimab being used together?
"City of Hope first studied the pembrolizumab/vibostolimab coformulation in 2010 and there are now 247 completed studies. At present, 1000 clinical trials are still active; many of these taking place in Chicago, Illinois."
Share this study with friends
Copy Link
Messenger